Annexon ANNX 深 滬
等待開盤 10-28 09:30:00 美东时间
3.76
+0.060
+1.62%
華盛通- 最 高3.84
- 今 開3.72
- 成交量 296.44万股
- 最 低 3.68
- 昨 收 3.70
- 總市值 7.13亿
- 52周最高 7.18
- 市盈率 靜 --
- 換手率 1.56%
- 52周最低 2.54
- 委 比 -79.29%
- 總股本 1.90亿
- 歷史最高 38.01
- 量 比 0.73
- 振 幅 4.32%
- 歷史最低 1.285
- 每 手 1
- 風險率 0.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股前瞻 | SpaceX、奈飞盘后将公布财报！存储再遭抛售，SK海力士跌近5%，高盛指对冲基金正减持科技股！
SpaceX、奈飞盘后将公布财报！存储再遭抛售，SK海力士跌近5%，高盛指对冲基金正减持科技股；布伦特原油升破110美元关口！创近五月来新高>>
10-20 20:22
美股大行评级 | 潜在涨幅523.44%！HC Wainwright & Co.上调Annexon目标价至25美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Annexon"买入"评级，目标价从14美元升至25美元；HC Wainwright & Co.：维持Alto Neuroscience"买入"评级，目标价从55美元升至60美元
10-20 12:36
Microsoft To Rally Around 25%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keefe, Bruyette & Woods cut the price target for Truist Financial Corporation (NYSE:TFC) from $55 to $54. Keef...
10-19 20:06
HC Wainwright & Co. Maintains Buy on Annexon, Raises Price Target to $25
HC Wainwright & Co. analyst Ananda Ghosh maintains Annexon (NASDAQ:ANNX) with a Buy and raises the price target from $14 to $25.
10-19 19:06
美股大行评级 | 潜在涨幅600.93%！Ascendiant Capital上调Aytu BioPharma目标价至15美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14.5美元升至15美元；摩根大通：维持Annexon"超配"评级，目标价从14美元升至15美元
10-01 19:18
Annexon to Present Patient Baseline Characteristics from Vonaprument Phase 3 ARCHER II Pivotal Trial for Geographic Atrophy at The Retina Society 59th Annual Scientific Meeting
Annexon, Inc. announced two oral presentations on vonaprument at The Retina Society's 59th Annual Meeting, highlighting Phase 2 vision protection findings and the design of the Phase 3 ARCHER II trial for geographic atrophy (GA). The presentations emphasize the replication of key baseline characteristics between Phase 2 and Phase 3 patient populations, aiming to confirm vonaprument's potential to protect vision across a broad GA population. Vonap...
09-24 12:00
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. granted stock options to two new non-executive employees under its 2022 Employment Inducement Award Plan. The options, totaling 275,500 shares with a $3.92 exercise price, vest over four years. The company focuses on developing targeted immunotherapies for neuroinflammatory diseases affecting nearly 10 million globally.
09-16 20:05
美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
09-02 14:07
JP Morgan Maintains Overweight on Annexon, Raises Price Target to $14
JP Morgan analyst Anupam Rama maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $10 to $14.
09-02 02:34
Annexon (ANNX) 2026年第二季度业绩电话会议：ARCHER II试验扩大，BLA申请按计划推进
Annexon的2026财年第二季度业绩电话会议涵盖了ARCHER II研究新的第24个月终点、FORWARD研究的初步数据，以及计划于第四季度提交的tanruprubart BLA（生物制品许可申请）。
08-17 08:01
